Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Withdrawn 2Completed 1

Sponsor Class

INDUSTRY 9OTHER 3OTHER_GOV 1NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 2Gynecologic 1

Conditions

Adenocarcinoma 2Uterine Cervical Neoplasms 1Ovarian Neoplasms 1Endometrial Neoplasms 1

Interventions

Cyclophosphamide 2042Radiotherapy 1859Cisplatin 1825Carboplatin 1533Gemcitabine 1434Paclitaxel 1289Bevacizumab 1270Docetaxel 1202pembrolizumab 1199Oxaliplatin 1160Capecitabine 1144Fluorouracil 1061Dexamethasone 971Rituximab 919Nivolumab 908Magnetic Resonance Spectroscopy 862Etoposide 839Doxorubicin 823Drug Therapy 792Radiosurgery 776Irinotecan 775Cytarabine 736fludarabine 716Leucovorin 676Lenalidomide 608fludarabine phosphate 564Temozolomide 552Radiation 541Filgrastim 540Cetuximab 537

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Interventional × bemarituzumab × Clear all
NCT07146919 2026-04-23

ANGELICA

Centre Leon Berard

Phase 1/2 Withdrawn
Gynecologic

Uterine Cervical Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT06967987 2026-01-21

BEMAFLOT

Institut Cancerologie de l'Ouest

Phase 2 Withdrawn
Tumor-Agnostic

Adenocarcinoma

NCT02213289 2021-04-08

PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression

University of Chicago

Phase 2 Completed
80 enrolled 14 charts
Tumor-Agnostic

Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡